73 results about "Dexmedetomidine" patented technology

The present disclosure describes systems and methods of estimating sedation level of a patient using machine learning. For example, the integration of multiple QEEG features into a single sedation level estimation system using machine learning could result in a significant improvement in the predictability of the levels of sedation, independent of the sedative drug used. The present disclosure advantageously allows for the incorporation of large numbers of QEEG features and machine learning into the next-generation monitors of sedation level. Different QEEG features may be selected for different sedation drugs, such as propofol, sevoflurane and dexmedetomidine groups. The sedation level estimation system can maintain a high performance for detecting MOAA / S, independent of the drug used.

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

Analgesic sublingual formulations of dexmedetomidine and methods of use thereof are provided for use in the prevention, treatment and management of pain and other conditions.

The present invention relates to compositions and methods use in pain reduction, including but not limited to, peripheral nerve blocks. In particular, the present invention relates to compositions and methods for the administration of perineural dexmedetomidine and ropivacaine in combination for increased antinociception in peripheral nerve blocks. In addition, this invention relates to any use of dexmedetomidine alone or in combination with other agents for the purpose of decreasing inflammation around peripheral nerves, thereby decreasing the potential for peripheral nerve injury. Further, the invention relates to the use of dexmedetomidine to reduce inflammation in the muscle to lessen or prevent muscle damage.

The invention relates to a method for preparing dexmedetomidine, which comprises the following steps of: 1) providing 4-imidazole formic ether, 2) reacting the 4-imidazole formic ether with stronger ammonia water and ammonium chloride so as to form 4-imidazole acid amide, 3) reacting the 4-imidazole acid amide with a cyaniding agent so as to form 4-cyano-group imidazole, and 4) generating the dexmedetomidine from the 4-cyano-group imidazole. The method of the invention needs no blocking group and de-blocking group, uses the cheap raw materials which are easily obtained, has simple route, requires mild reaction condition, has low demand on production device and has a small volume of the three wastes. The prepared dexmedetomidine has high yield coefficient and high purity and is fit for industrial production.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.

The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.

The invention provides compositions and methods for treating diseases and conditions, including systemic diseases and conditions, through an intravenous administration of a selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The amounts of the selective α-2 adrenergic receptor agonists are substantially lower than the amounts normally used to cause sedation. The compositions preferably include dexmedetomidine.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

The invention relates to a method for preparing dexmedetomidine hydroch. The method particularly includes the following steps that 1, dispinner medetomidine is dissolved in methyl alcohol and mixed with a right-handed resolving agent according to the molar ratio of 1:0.4-0.6, stirring is conducted for 2-3 hours at the heating temperature of 60-80 DEG C, diethyl ether is added, cooling, still standing, crystallization and filtering are conducted, a mother solution and a left-handed resolving agent are mixed according to the molar ratio of 1:0.4-0.6, stirring and crystallization are conducted for 24 hours, and dexmedetomidine is obtained after filtering is completed; 2, obtained dexmedetomidine is placed in HCl / diethyl ether, and the end product dexmedetomidine hydroch is formed. Compared with the prior art, dexmedetomidine hydroch is prepared at low cost; the synthetic route is short, dexmedetomidine hydroch with high purity can be prepared, isomers are not detected, quality meets the newest standard of the pharmacopeia, and industrial production is facilitated. Adopted raw materials are low in cost, reaction conditions are moderate, and the method can be applied to actual production.

The invention provides a method for preparing dexmedetomidine and a hydrochloride thereof. Specifically, a composition of a carbon-carbon hydrogenation reduction catalyst and (R,S)-Duanphos is used asa catalyst for chiral catalytic reduction of a double bond, and the dexmedetomidine with an enantiomeric excess being 99.9% can be directly obtained. The preparation method provided by the inventionis short in synthetic route, and the product does not need chiral resolution and is high in yield.

The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.

The invention relates to the field of pharmaceutical compositions, and especially relates to a pharmaceutical composition preventing postoperative delirium. The provided pharmaceutical composition contains a pharmaceutical solvent carrier and dexmedetomidine or pharmaceutically-acceptable salts dissolving in the solvent carrier. The pharmaceutical composition is applicable to improve postoperative patient sleep structure, thereby improving patient sleep quality. The pharmaceutical composition is capable of preventing postoperative patient delirium, also is capable of mitigating patient pain, is safe to use and low in cost, and is usable by being matched with one or more of other sedatives, narcotics, hypnotics and opioids.

The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

The invention provides a preparation method of dexmedetomidine and an intermediate product thereof. Concretely, the method comprises the step of synthesizing a compound shown as a formula I by using SuzuKi coupling reaction. The invention also provides a method for continuously preparing the dexmedetomidine and the intermediate product thereof. The process has the advantages of short steps, high yield, operation simplicity, high purity and the like, and is suitable for industrial mass production.

The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.

The invention discloses application of dexmedetomidine and medicinal salts of the same. The dexmedetomidine or the medicinal salts of the same are used for preparing a medicine used for sedateness by preoperative patients, intraoperative patients, postoperative patients and patients requiring trachea cannulas and endoscope cannulas. The medicine contains clinically effective quantity of the dexmedetomidine or the medicinal salts of the same, and the dexmedetomidine or the medicinal salts of the same is an only active agent and made into the medicine for intravenous administration; and the medicine is fed under the condition of administration until the blood plasma concentration is between 0.1 and 2 ng / ml. The invention increases a method for using the dexmedetomidine or the medicinal salts of the same, and not only widens the medicine application of the dexmedetomidine but also can make more non-ICU patients acquire good mitigative and analgesic effects and reduce the dosage of other similar medicines and the incidence rate of untoward reactions.

The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and / or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.

The invention belongs to the technical field of drug fluid distribution. Compared with an injection drug administration way, a device for drugs for external use always stores more drugs, and the drugsare applied in batches in various occasions. The device for drugs for external use always has a long use period and a relatively poor storage condition, requirements for stability of medicaments in the device for drugs for external use are higher, and medicament auxiliary material selection and compatibility of packing materials are key factors which are mainly considered and screened. When the device for drugs for external use is used for multiple times or only a small quantity of liquid is required for loading drugs, dosage delivery is insufficient and / or differences are large, and a situation that active ingredients degrade is usually associated immediately. Although most cases are as usually known that medicament stability is insufficient and active ingredients degrade to enable a curative effect to get worse, the thought of technicians in the field is restricted. The invention makes an in-depth study to discover a reason for generating an unstable curative effect in another accompanying drug administration utilization process, and on the basis, a novel drug fluid distributor is provided.

Analgesic topical formulations of dexmedetomidine and methods of use thereof in the treatment and management of pain and other conditions.

The present invention relates to a pharmaceutical product comprising a transnasal dexmedetomidine composition. Specifically, the present invention relates to a pharmaceutical product comprising a nasal administration dexmedetomidine pharmaceutical composition and a device, the product having excellent stability.